0
Pulmonary Vascular Disease |

Factors Affecting the Morbidity and Mortality of Pulmonary Thromboembolism Patients in Long Term Follow-up

Fusun KolatKirkpantur, MD; I.Kivilcim Oguzulgen, MD; Numan Ekim, MD
Author and Funding Information

Gazi University School of Medicine, Ankara, Turkey


Chest. 2013;144(4_MeetingAbstracts):846A. doi:10.1378/chest.1700783
Text Size: A A A
Published online

Abstract

SESSION TITLE: DVT/PE/Pulmonary Hypertension Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: There is limited number of studies regarding the predictive factors for prognosis of Pulmonary thromboembolism (PE), which is a recurrent disease and has many chronicle sequelas. The aim of this study is to investigate the prognosis of PTE (in terms of recurrence, complications, survival and mortality) and factors affecting the prognosis.

METHODS: Patients who were hospitalized for PTE between January 1998-January 2010, whose files consisted valid clinical and contact information were involved in the study (n: 245). The information regarding PTE treatment, recurrence, survival, complications and development of malignancy were recorded.

RESULTS: Mean treatment time was10.4±13.4 months. Recurrence and mortality rates were 13.0% and 14.3% respectively. Co-existent cancer (HR: 2.711, p=0.04) and immobility (HR: 2.846, p=0.014) were independent predictors of mortality. Atherosclerotic cardiac disease (OR: 2.4, p=0.04) and diagnosis of DVT in follow-up (OR: 23, p=0.0001) were independent predictors of recurrent PE. PE complications like chronic thromboembolic pulmonary hypertension (%0.8) and chronic respiratory failure (%3.7) were more frequently observed in patients with older age, more comorbid conditions and recurrent PE. Malignity was diagnosed in 5.7% of idiopathic cases during the follow up, however this ratio was not different from the patients with risk factors for PE.

CONCLUSIONS: Pulmonary thromboembolism is an important disease with high mortality rate and severe complications.

CLINICAL IMPLICATIONS: To improve the personal and financial outcomes of the disease all risk factors affecting the prognosis (recurrence, complications and mortality) should be investigated to develop more effective treatment and follow-up strategies.

DISCLOSURE: The following authors have nothing to disclose: Fusun KolatKirkpantur, I.Kivilcim Oguzulgen, Numan Ekim

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543